Search results
Results from the WOW.Com Content Network
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Drug Trade name Type Main indications Company Sales (USD millions/year) ∆ vs 2014 1 Adalimumab: Humira Biologic Rheumatoid arthritis: AbbVie Inc. 14,012 1,469 2 Ledipasvir/sofosbuvir: Harvoni Small molecule Hepatitis C: Gilead Sciences: 13,864 11,737 3 Etanercept: Enbrel Biologic Rheumatoid arthritis: Amgen. Pfizer. 8,697 4,009 4 Infliximab ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Included here are companies engaged not only in pharmaceutical development, but also supply chain management and device development, including compounding pharmacies. Firms with no marketed products but which are working on pharmaceutical development as well as mature firms with a post-marketed portfolios have been included here.
Casgevy, at a price of $2.2 million in the U.S. -- and very little competition to speak of, at least for now -- could easily vastly exceed the $1 billion in sales milestone.
By mid-2014, Accelerator, a biotech investment firm, had raised more than US$30 million from investors, including Eli Lilly and Company, Pfizer, and Johnson & Johnson, for initial funding to create biotechnology startups at the Alexandria Center for Life Science, which encompasses more than 700,000 square feet (65,000 m 2) on East 29th Street ...
Sales of J&J's oncology drugs rose nearly 19% worldwide for the quarter, driven by more than $3 billion for multiple myeloma treatment Darzalex, up 20.7% or more than $500 million from a year ago.
(Reuters) -Merck & Co on Thursday raised its annual profit and revenue forecast on the back of strong sales for its blockbuster cancer drug Keytruda. The New Jersey-based drugmaker said it ...